Printer Friendly

Frequency and risk of metabolic syndrome in prediabetics versus normal glucose tolerant subjects " a comparative study.

Byline: Shahid Ahsan, Syed Danish Haseen Ahmed, Shah Nawaz Jamali, Muhammad Imran, Muhammad Saiful Haque and Rashida Qasim

Abstract

Objective: To compare the frequency and risk of metabolic syndrome in pre-diabetics against normal glucose- tolerant subjects attending diabetes screening camps in an urban centre.

Methods: The cross-sectional study was carried out at the Jinnah Postgraduate Medical Centre, Karachi, from January to August, 2008, and comprised subjects recruited through diabetes screening camps. They were greater than 30 years of age, without prior history of diabetes and were screened through fasting plasma glucose and 2-hour oral glucose tolerance test. Demographic, anthropometric, clinical and biochemical measurements were done. Frequency of different components and their constellation as metabolic syndrome were determined according to the Adult Treatment Panel-III criteria. Relative risk was estimated to find the risk of metabolic syndrome in pre-diabetics versus normal glucose-tolerant subjects.

Results: The study sample comprised 80 subjects; 40(50%) normal glucose-tolerant in Group A and 40(50%) pre- diabetics in Group B. In Group A, there were 25(62.5%) men and 15(37.5%) women, while Group B had 22(55%) men and 18(45%) women. The mean age in Group A was 38.085.35 years, while in Group B it was 39.096.12 years. The frequency of various cardiovascular risk factors was higher in pre-diabetics (pless than 0.05). Central obesity was the most prevalent risk factor (85%, CI: 75.74-96.06), followed by low levels of high density lipoprotein (82.5%, CI: 72.64-94.27), raised triglycerides (67.5%, CI: 55.35-82.01), hypertension (57.5%, CI: 44.68-72.82), and fasting plasma glucose greater than 100mg/dl (42.5%, CI: 29.68-57.82). Metabolic syndrome was found in 23(57.5%) in Group B compared to 9(22.5%) Group B, according to Adult Treatment Panel-III criteria. Calculated relative risk indicated that Group B was 1.9 times more prone to be suffering from metabolic syndrome compared to Group A.

Conclusions: Pre-diabetics were more prone to developing cardiovascular disorders than normal glucose-tolerant subjects.

Keywords: Metabolic syndrome, Risk factors, Pre-diabetes. (JPMA 65: 496; 2015)

Introduction

Over the last two decades, there has been a tremendous increase in the number of people with metabolic syndrome (MeS).1 Even in the United States its prevalence has risen promptly from 22% in 1988-1994 to 34.5% in 1999-2002.2 A similar trend was observed in other parts of the world in general and in Asia in particular where prevalence of MeS has been reported consistently to range from 10% to 40%.3-5 Pakistan is also confronting a growing epidemic of MeS with reported prevalence of 34.8% and 40% in urban and rural areas respectively.6,7 The high prevalence of MeS has important health implications and is considered to be a driver of the modern day epidemics of diabetes and cardiovascular diseases (CVDs).8

The term 'prediabetes' is cumulative for two intermediate conditions - impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT).9 Glucose intolerance in MeS could be IFG, IGT or diabetes. Presence of any one of these glucose abnormalities, though not obligatory, along with other factors is suffice to make the diagnosis of MeS.8,10 Therefore, in some individuals, MeS co-exists with glucose dys-regulation.11 While in others MeS is present without glucose dysregulation.12,13 Whether or not MeS has component of glucose dysregulation, it has equal prognostic value for cardiovascular outcomes. However, propensity to have CVD is increased when glucose dysregulation is present as a component of MeS.14 This predisposition rises further when diabetes is present as a component of MeS.11 Due to increased predilection for CVDs, MeS and pre-diabetes both become leading health concerns.

The study was planned to determine the distribution of various cardiovascular risk factors and to compare the frequency and risk of MeS between normal glucose-tolerant (NGT) and pre-diabetic subjects.

Subjects and Methods

The observational cross-sectional study was carried out at the Department of Biochemistry, Basic Medical Sciences Institute, Jinnah Postgraduate Medical Centre, Karachi, from January to August 2008, and comprised subjects recruited through various diabetes screening camps. Of all those screened, the subjects were selected on the basis of systematic random technique. Methodology of the present study was described in detail elsewhere.15

A detailed information leaflet was provided to all consenting participants to whom study objectives, procedures and the risks and benefits involved were explained and they were assured about the confidentiality of data. An informed consent was signed by each participant. After an overnight fast of at least 10-12 hours, blood was collected to estimate fasting plasma glucose (FPG), serum cholesterol, serum triglyceride (TG) and high density lipoprotein (HDL) cholesterol level. Low density lipoprotein (LDL) cholesterol was calculated by using the Friedewald's equation.16 A solution of 75g of glucose dissolved in water was administered and 3ml of blood was drawn 2 hours later for estimation of glucose. Demographic, anthropometric and clinical parameters of each subject were collected on an interviewer-administered questionnaire. Anthropometric measurements, including weight, height and waist measurements, were obtained using standardised techniques on the screening day.17

Folding screens were used to isolate the subjects. Blood pressure was recorded in the sitting position in the right arm to the nearest 2 mmHg with a mercury sphygmomanometer.

Due to unknown local population of pre-diabetics, the priori sample size was not calculated. However, screening for pre-diabetics continued along the study period until the power of the study was statistically attained. Power based on normal approximation with continuity correction was calculated to be 85.74% with 95% confidence interval (CI) by Open Epi.18

Based on FPG results and two-hour oral glucose tolerance test (OGTT ), subjects were categorized according to American Diabetes Association (ADA) and World Health Organisation (WHO)19 classification of diabetes into NGT, IFG, IFG with IGT, IGT and diabetic groups. Individuals having IFG (greater than 110-less than 125mg/dl) and/or IGT (greater than 140-less than 200 mg/dl) were grouped together as pre-diabetics. Different International bodies have defined the term MeS. Among all of them, the National Cholesterol Educational Programme-Adult Treatment Panel-III (NCEP-ATP III) is the most widely used definition due to its simple approach for diagnosing MeS.20-22

Frequency of individual risk factors and their constellation as MeS was determined according to ATP-III guidelines between NGT and pre-diabetic subjects and expressed in simple frequencies and percentages with 95% CI. Relative risk (RR) was estimated to find the risk of MeS in pre- diabetics compared to NGT subjects.

Results

Of the 608 subjects screened, 83(13.6%) were found to have pre-diabetes. The final study sample comprised 80 subjects; 40(50%) NGT and 40(50%) pre-diabetics. Among

Table-1: Comparison of demographic, anthropometric, clinical and biochemical characteristics of normal glucose tolerant and prediabetic (n=80).

Biophysical###Normal Glucose###Prediabetes###p-value

parameters###Tolerant (Control)

N###40###40

Males###25(62.5%)###22(55%)###0.496

Females###15(37.5%)###18 (45%)

Age (years)###38.085.35###39.096.12###0.474

BMI (kg/m)###26.663.12###29.623.19###0.000

Waist (cm)###86.308.13###93.958.09###0.000

Systolic BP (mmHg)###116.3811.20###124.018.98###0.032

Diastolic BP (mmHg)###80.257.67###86.0011.16###0.009

Fasting Plasma Glucose (mg/dl )###89.9810.36###99.3012.41###0.000

2 hour Plasma Glucose ( mg/dl)###112.259.17###175.8018.91###0.000

Cholesterol (mg/dl)###169.0336.34###201.1844.21###0.001

Triglyceride (mg/dl)###138.7062.22###185.0578.18###0.004

High density lipoprotein (mg/dl)###42.107.46###37.556.64###0.005

Low density lipoprotein (mg/dl)###102.9334.55###125.1943.19###0.013

Table-2: Comparison of components of metabolic syndrome in normal glucose tolerant and prediabetic subjects.

Cardiovascular###NGT###Prediabetic###p-value

risk factors###n=40###n=40

Central obesity###20 (50%)###34 (85%)###0.001

(waist greater than 80 90 cm)###(37.03-65.49)###(75.74-96.06)

HDL###22 (55%)###33 (82.5%)###0.008

(less than 40 / 50mg/dl)###(42.09-70.41)###(72.64-94.27)

TG###13(32.5%)###27 (67.5%)###0.002

(greater than 150 mg/dl)###(20.35-47.01)###(55.35-82.01)

HTN###13 (32.5%)###23 (57.5%)###0.025

(greater than 130/85 mmHg)###(20.35-47.01)###(44.68-72.82)

FPG###6 (15%)###17 (42.7%)###0.007

(greater than 100 mg/dl)###(5.74-26.06)###(29.68-57.82)

Table-3: Contingency table for calculating risk of metabolic syndrome in prdiabetics.

Glucose Tolerance###Metabolic Syndrome###Total

###Present###Absent

Prediabetes###17###23###40

NGT###9###31###40

Total###26###54###80

The NGTs, there were 25(62.5%) men and 15(37.5%) women, while there were 22(55%) men and 18(45%) women pre-diabetics. The mean age was 38.085.35 years, and 39.096.12 years respectively (Table-1).

The frequency of various cardiovascular risk factors was higher in pre-diabetics (pless than 0.05). Central obesity was the most prevalent risk factor (85%, CI: 75.74-96.06), followed by low HDL (82.5%, CI: 72.64-94.27), raised TG(67.5%, CI: 55.35-82.01), hypertension (57.5%, CI: 44.68-72.82), and FPG100mg/dl (42.5%, CI: 29.68-57.82) (Table-2)

MeS was found in 23(57.5%) pre-diabetics compared to 9(22.5%) NGTs, according to ATP-III criterion (Figure). Calculated RR indicated that pre-diabetics were 1.9 times more prone to be suffering from MeS compared to NGTs (Table-3).

Discussion

MeS encompasses a myriad of seemingly unrelated disorders such as hypertension (HTN), hyperlipidaemia, atherosclerosis and inflammation.20 The current consensus definition of MeS includes increased blood glucose level as one of its components. Others are abdominal obesity, elevated blood pressure (BP), elevated TG, and reduced HDL cholesterol (HDL-c). Any three of these five components or any two along with central obesity confer a diagnosis of the syndrome.21 Pre-diabetes, being one of the components of MeS, shares the same underlying metabolic soil of insulin resistance, therefore, considerable overlap exists between the two conditions.22

In the present study a higher frequency of cardiovascular risk factors were found in pre-diabetics compared to NGT subjects. Increased waist circumference, which is a measure of central obesity, and low HDL-c were the more frequent risk factors, 68% and 69% respectively. Increased waist circumference indicates intra-abdominal accumulation of adipose tissues. These tissues release excess fatty acids and a variety of adipokines that seemingly elicit metabolic risk factors that predispose to CVD. Altered adipokines secretions are claimed to be the missing link that connects obesity with glucose dysregulation.23,24 Increased frequency of waist is in accordance with the growing epidemic of obesity in the country. The epidemiological survey of Urban Karachi, Pakistan, also revealed that 68% and 46% of women and men greater than 25 years of age respectively were obese, according to Asian cut-off for waist circumference.

Beside central obesity, low level of HDL-c is a common feature encountered in MeS. Studies revealed that not only subjects with MeS but nearly 10-15% of healthy subjects also had HDL-c levels less than the 15th percentile for age and gender. According to different studies, nearly 65-83% patients with MeS had low HDL-c(25-28). A study from Pakistan also reported low HDL-clevels among all females with MeS.29 In the present study, 86.7% females with pre- diabetes had low HDL-c level. A low level of HDL-c is not only a component trait of MeS, but it is also an independent risk factor for coronary artery disease (CAD).30 In various prospective epidemiological studies, the relationship between low HDL-c and CAD has been found.31-34 According to a study, 68.5% people in the community and 81% patients with type 2 diabetes had low HDL-c levels.35

Our observation for low HDL-c in pre-diabetics is consistent with the aforementioned study even though we searched low HDL-c retrospectively in pre-diabetics as component of MeS.

Increased TG is another characteristic lipid disturbance seen in MeS. An increasing number of subjects in the present study, including those with pre-diabetes, had higher TG levels. In the present study, 50% participants had hypertriglyceridemia, and among them 34% had pre- diabetes. This is nearly in between the reported frequency of hypertriglyceridaemia in a community-based and in a hospital-based study on type 2 diabetics where observed frequencies were 27.2% and 54% respectively.35,36

Hypertriglyceridaemia not only has strong association with CVD, but it may also predict subsequent development of type 2 diabetes in subjects with IFG.37,38 It is therefore suggested that subjects with hypertriglyceridaemia should be kept under surveillance to rule out type 2 diabetes. Hypertriglyceridaemia in pre-diabetes is due to insulin resistance, which leads to increased hepatic very low density lipoprotein (VLDL) production and defective removal of chylomicrons and chylomicron remnants that often reflects poor glycaemic control.39

More than half of people with pre-diabetes in the present study suffered from HTN (57.5%). This may be due to association of BP with obesity and insulin resistance. Though the exact mechanism of HTN in pre-diabetes is not understood, plausibly it may be caused by mechanisms that connect insulin resistance with HTN in MeS. Accumulating data indicated that insulin stimulates renal sodium re- absorption.40-42 This anti-natriuretic effect is preserved, and may be increased in individuals with insulin resistance and this effect may play an important role in the development of HTN in MeS. Another proposed mechanism by which HTN is linked with central obesity and, thus, by pre-diabetes is over- activation of sympathetic nervous system and renin- angiotensin aldosterone system (RAAS) that consequently cause sodium retention and volume expansion, endothelial dysfunction and alteration in renal function.43-45

Based on the prevalence of individual components of MeS it is argued that fasting hyperglycaemia is the last component that developed in the natural course of this syndrome.46 The present study contradicts this hypothesis. We explored the presence of MeS in some rather than in all pre-diabetic subjects. This suggests that the expression of various components of this syndrome do not follow any defined sequence.

Our study showed higher frequency of MeS in pre-diabetics according to ATP-III guidelines. This increased frequency of MeS in pre-diabetics was consistent with other studies originating from the region.47,48 Possible reason for the higher rate of MeS in pre-diabetics may be the common metabolic thread of insulin resistance in both conditions.

Our study explored an increased rate of various cardiovascular risk factors among study population. It also discovered an increased frequency of MeS in pre-diabetic subjects by ATP-III criteria. The study thus underscores the importance of keeping an eye on various risk factors of MeS in pre-diabetics to avoid impending cardiovascular events.

Though the present study did attain statistical power, due to small sample size, a multi-centre prospective study on a larger population is needed to ascertain its external validity.

Conclusion

Pre-diabetes is generally regarded as a condition of glucose dysregulation leading to diabetes and not much importance is given to its other consequences. This observational study showed a high frequency and risk of MeS in pre-diabetics compared to NGT subjects. Thus pre-diabetes may not only be considered a condition of impending diabetes, but measures should also be taken to lessen the awaiting cardiovascular events.

References

1. Basit A, Shera AS. Prevalence of metabolic syndrome in Pakistan. Metab Syndr Relat Disord 2008; 6: 171-5.

2. Sinclair K A, Bogart A, Buchwald D, Henderson JA. The prevalence of metabolic syndrome and associated risk factors in northern plains and southwest American Indians. Diabetes Care 2011; 34: 118-20.

3. Patel A, Huang KC, Janus ED, Gill T, Neal B, Suriyawongpaisal P, et al. Is a single definition of the metabolic syndrome appropriateA comparative study of the USA and Asia. Atherosclerosis 2006; 184: 225-32.

4. Kim HM, Kim DJ, Jung IH, Park C, Park J. Prevalence of the metabolic syndrome among Korean adults using the new International Diabetes Federation definition and the new abdominal obesity criteria for the Korean people. CMAJ 2006; 175: 1071-7.

5. Deepa M, Farooq S, Datta M, Deepa R, Mohan V. Prevalence of metabolic syndrome using WHO, ATPIII and IDF definitions in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES-34). Diabetes Metab Res Rev 2007; 23: 127-34.

6. Hydrie MZI, Shera AS, Fawwad A, Basit A, Hussain A. Prevalence of Metabolic Syndrome in Urban Pakistan (Karachi): Comparison of Newly Proposed International Diabetes Federation and Modified Adult Treatment Panel III Criteria. Metabol Syndr Relat Disord 2008; 7: 119-24.

7. Wierzbicki AS, Nishtar S, Lumb PJ, Lambert-Hammill M, Turner CN, Crook MA, et al. Metabolic syndrome and risk of coronary heart disease in a Pakistani cohort. Heart 2005; 91: 1003-7.

8. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. [online] [cited 2014 May 14]. Available from: URL: http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition .pdf/.

9. Fonseca VA. Early identification and treatment of insulin resistance: impact on subsequent prediabetes and type 2 diabetes. Clin Cornerstone 2007; 8 Suppl 7: S7-18.

10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486-97

11. Grundy SM, Pre-Diabetes, Metabolic Syndrome and Cardiovascular Risk. J Am Coll Cardiol 2012; 59: 635-43.

12. Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, Claude JR, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris Prospective Study, ten years later. Horm Metab Res 1985;15 (Suppl): 41- 6.

13. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-81,

14. Mottillo S, Kristian B, Filion KB, Genest J, Joseph L, Pilote L, et al. The metabolic syndrome and cardiovascular risk, a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 1113-32.

15. Ahsan S, Mamji MF, Ahmed S, Ahmed SDH, Numan K, Haque MS. Role of adiponectin as a biomarker of prediabetes. Med Channel 2012; 18: 72-5.

16. Berk ES, Korera AJ, Boozer CN, Pi-Sunyer FX, Johnson JA, Albu JB. Adiponectin level during low and high fat eucaloric diet in lean and obese women. Obes Res 2005; 13: 1566-71.

17. Friedewald WT, levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.

18. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version. www.OpenEpi.com, updated 2014/09/01, accessed 2014/09/04.

19. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.

20. Catalano PM, Mouzon SH. Is it time to revisit the Pedersen hypothesis in the face of the obesity epidemic Am J Obstet Gynecol 2011; 204: 479-87.

21. Standl E. Aetiology and consequences of the metabolic syndrome. Eur Heart J Suppl 2005; 7: D10-3

22. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of Metabolic Syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004; 109: 433-8.

23. Grundy SM. A changing paradigm for prevention of cardiovascular disease: emergence of the metabolic syndrome as a multiplex risk factor. Eur Heart J Suppl 2008; 10 (suppl B): B16-23.

24. Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev 2007; 21: 1443-55.

25. Clee SM, Kastelein JJ, van Dam M, Marcil M, Roomp K, Zwarts KY, et al. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J Clin Invest 2000; 106: 1263-70.

26. Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Metabolic syndrome in urban Asian Indian adults: a population study usingmodified ATP III criteria. Diab Res Clin Pract 2003; 60: 199-204.

27. Al Lawati JA, Mohammed AJ, Al Hinai HQ, Jousilahti P. Prevalence ofthe metabolic syndrome among Omani adults. Diabetes Care 2003; 26:1781-5

28. Solymoss BC, Bourassa MG, Campeau L, Lesperance J, Marcil M, VargaS. Incidence, coronary risk profile and angiographic characteristics of prediabeticand diabetic patients in a population with ischemic heart disease. CanJ Cardiol2003; 19: 1155-60.

29. Mohsin A, Zafar J, Nisar YB, Imran SM, Zaheer K, KhizarB, et al. Frequency of the metabolic syndrome in adult type2 diabetics presenting to Pakistan Institute of Medical Sciences. JPMA 2007; 57: 235-8.

30. Takata K, Saku K, Ohta T, Takata M, Bai H, Jimi S, et al. A new case of apoA-I deficiency showing codon 8 nonsensemutation of the apoA-I gene without evidence of coronary heart disease. Arterioscler Thromb Vasc Biol 1995; 15:1866-74.

31. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707-14.

32. Despres JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. HDL- cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis 2000;153: 263-72.

33. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124 Suppl: S11-S20.

34. Genest JR, Marcil M, Denis M, Yu L. High density lipoproteins in health and in disease. J Invest Med 1999; 47: 31-42.

35. Basit A, Hydrie ZI, Shera SA, Khan A, Ismail J, Molla N, et al. Poster presentation, PS 17, Prevalence of metabolic syndrome among adults 25 year and above in Urban Karachi 41st EASD Annual Meeting Athens, Greece: 2005;10-15.

36. Basit A, Hydrie MZI, Hakeem R, Ahmedani MY, Masood Q. Frequency of chronic complications of type 2 diabetes. J Coll Physicians Surg Pak 2004; 2: 79-83.

37. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81: 7B-12B.

38. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115: 450-8.

39. Kreisberg RA. Diabetic dyslipidemia. Am J Cardiol 1998; 82: 67U-73U.

40. Miller JH, Bogdonoff MD.Antidiuresis associated with administration of insulin. J Appl Physiol 1954, 6: 509-12.

41. Nizet A, Lefebvre P, Crabbe J. Control by insulin of sodium potassium and water excretion by the isolated dog kidney. Pflugers Archiv 1971, 323: 11-20.

42. DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 1975; 55: 845-55.

43. Reaven GM. Insulin resistance and itsconsequences. In: LeRoith D, Taylor SI, Olefasky JM, eds. Diabetes mellitus: a fundamental and clinical text. 3rd ed. Philadelphia: Lippincott, Williams and Wilkins, 2004: pp. 899-915.

44. Low Wang C, Goalstone ML, Draznin B. Molecular mechanisms of insulin resistance that impact cardiovacsular biology. Diabetes 2004; 53: 2735- 40.

45. Sowers JR, Fronlich ED. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North Am 2004; 88: 63-82.

46. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.

47. Al-Shafaee MA, Ganguly SS, Bhargava K, Duttagupta KK. Prevalence of metabolic syndrome among prediabetic Omani adults: a preliminary study. Metab Syndr Relat Disord 2008; 6: 275-9.

48. Phanikrishna SBB, Rao EV. Prevalence of metabolic syndrome and insulin resistance in normal and abnormal glucose tolerant subjects in South India. Int J Appl Biol Pharm Tech 2011; 2: 160-6.

49. Statistical Calculations. [online] [cited 2013 Aug 31]. Available from: URL: http://www.statpages.org/ctab2x2.html.
COPYRIGHT 2015 Asianet-Pakistan
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Journal of Pakistan Medical Association
Geographic Code:9PAKI
Date:May 31, 2015
Words:3990
Previous Article:Histological changes induced by tamoxifen versus tamoxifen plus 13-cis-retinoic acid on rabbit uterine glands.
Next Article:Lumbosacral dysraphism as cause of neurogenic bladder: Magnetic Resonance Imaging based study from SIUT Pakistan.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |